Apellis Pharmaceuticals Announces That APL-2 Met Its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-...
August 24, 2017
MaxCyte, Inc. - First Day of Dealings on AIM
March 30, 2016
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
November 8, 2017
MaxCyte to Host Symposium at BIO Asia 2007
January 16, 2007
Delivering on the Promise of Cellular Therapies
Gaithersburg, Maryland - MaxCyteInc., a clinical stage therapeutic company and pioneer in clinical scale, non-viral cell loading systems, announces that it is hosting a symposium on "Delivering on the Promise of Cellular Therapies - Engineered Cells May Provide the Solution" during BIO-Asia 2007 at the Grand Hyatt in Tokyo, Japan on Tuesday January 30th from 3:00 p.m. to 4:30 p.m. (local time).
Opinion-leading physicians and scientists will share their knowledge and experience about practical approaches to cell therapy and regenerative medicine. Speakers will be Duncan J. Stewart, M.D., Associate Professor, University of Toronto; Malcolm K. Brenner, M.D., Director of the Center for Cell and Gene Therapy at Baylor College of Medicine; Jane Lebkowski , Ph.D., Vice President of Regenerative Medicine, Geron Corporation; and Sinclair Dunlop, Director, MASA Life Science Ventures.
"We are honored and excited to host such distinguished scientists for this event," said Douglas A. Doerfler, President and CEO of MaxCyte, "Recent advances in cell biology coupled with advances in engineering cells make it possible for cells to be safely and efficiently engineered to produce more effective therapies, thereby improving patient outcomes in diseases where existing therapies are inadequate."
MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies. The Company's proprietary ex vivo cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility which are fundamental to successful cell-based therapies. MaxCyte has demonstrated the value of its versatile technology in partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include: a Phase I/II clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addition there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at CBER.